At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
BTX 1204 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating BTX 1204 and Vehicle for Atopic Dermatitis. Completed, enrolled 200 participants across 31 sites in 3 countries.
Detailed Summary
This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, New Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartFeb 2019
Primary CompletionJan 2020
Study CompletionMar 2020
TodayJul 2026
First PostedJan 31, 2019
Enrollment StartFeb 4, 2019
Primary CompletionJan 27, 2020
Study CompletionMar 4, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.4 years ago
Interventions
BTX 1204drug
BTX 1204 liquid formulation
Vehicledrug
Vehicle liquid formulation